GLP-1 RA use more than doubled between 2017 and 2022, indicating significant increases among people with and without diabetes.
A recent review found that most drugs for the management of obesity do not improve heart health or quality of life.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results